1. Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–72.
2. FDA. Immunogenicity testing of therapeutic protein products —developing and validating assays for anti-drug antibody detection. Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). 2019 [cited 2019 July]; Available from: https://www.fda.gov/media/119788/download. Accessed 5 Nov 2020.
3. EMA. Guideline on immunogenicity assessment of therapeutic proteins European Medicines Agency, EMA; 2017 [cited 2019]; [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 5 Nov 2020.
4. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1–2):1–9. https://doi.org/10.1016/j.jim.2008.01.001.
5. Shankar G, Pendley C, Stein K. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555–61. https://doi.org/10.1038/nbt1303.